AIM ImmunoTech Inc.

AI-generated fair value estimate for this company.

Method: Net cash plus risk-adjusted NPV: net cash of about $4.91M ($9.9M cash less $4.99M total liabilities) equals $0.161/share across 30.44M shares; added a risk-adjusted NPV for the Ampligen (rintatolimod) plus AstraZeneca durvalumab pancreatic-cancer combination program assuming a $250M peak-sales case, 25% owner-economics margin, 12% probability of success (reflecting positive Phase 2 DURIPANC interim data moving toward planned Phase 3), and a 0.43 discount factor for ~6 years to launch at a 15% discount rate, giving about $3.2M or $0.106/share for a total of ~$0.27/share.

Reasoning: AIM ImmunoTech is a legitimate clinical-stage immuno-pharma company with small existing Ampligen sales (~$88-95K/yr from named-patient/Argentina use) and a genuine ongoing Phase 2 pancreatic-cancer combination trial with positive interim readouts, so a net-cash-plus-pipeline-rNPV approach fits far better than a DCF on its negligible product revenue.